Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients

GlobeNewsWire • Feb 17, 2026

FTRE vs. PRTA: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Feb 13, 2026

Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.

GlobeNewsWire • Jan 29, 2026

FTRE or ACAD: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 28, 2026

Fortrea Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE

NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

PRNewsWire • Jan 20, 2026

Fortrea Holdings Inc. (FTRE) Shows Fast-paced Momentum But Is Still a Bargain Stock

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortrea Holdings Inc. (FTRE) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Investment Research • Jan 14, 2026

Fortrea Holdings Inc. (FTRE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fortrea Holdings Inc. (FTRE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

FTRE vs. ACAD: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Fortrea Holdings Inc. (FTRE) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jan 12, 2026

Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco).

GlobeNewsWire • Jan 9, 2026

Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last?

Fortrea Holdings Inc. (FTRE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Jan 7, 2026